RHOG, FAS edits extend CAR‑T survival

CAR-T therapy is engineered immune-cell therapy — basically, you take a patient’s T cells, give them a synthetic receptor, and send them back to hunt cancer. It has worked spectacularly in some blood cancers. Solid tumors have been the hard part for years. The news here is that gastric cancer finally produced a randomized CAR-T result that looks like a real breakthrough — but the viral version of the story mixed that clinical win together with separate gene-editing research. (thelancet.com) ### What actually happened? The clinical result came from satricabtagene autoleucel — satri-cel — a Claudin18.2-targeted autologous CAR-T made by CARsgen. In a randomized phase 2 trial in previously treated advanced gastric or gastro-oesophageal junction cancer, satri-cel beat physician’s-choice therapy and became the first randomized controlled CAR-T win reported in a solid tumor setting. (thelancet.com) ### What were the numbers? The headline efficacy result was progression-free survival: 3.25 months with satri-cel versus 1.77 months with standard treatment. Median overall survival was 7.92 months versus 5.49 months. That survival gap is where the “about 40% longer” line comes from — but the trial’s primary punch was disease control first, then a survival signal on top. (thelancet.com) ### Why is Claudin18.2 such a big deal? Claudin18.2 is a surface protein found in a subset of gastric and related cancers, which makes it a usable target for cell therapy. That matters because solid tumors usually fail CAR-T for boring but brutal reasons — the target is patchy, the cells do not traffic well, or the tumor micro(thelancet.com) both druggable and clinically relevant. (ascopubs.org) ### So where do RHOG and FAS come in? RHOG and FAS are not the source of the satri-cel gastric survival result. They come from newer mechanistic work on how to make CAR cells last longer and resist dysfunction. One 2025 Nature paper flagged RHOG knockout as a strong enhancer of CAR-T performance, including in combination with FAS knockout. Another Nature Cancer pape(ascopubs.org) persistence by interrupting a self-limiting death circuit. (nature.com) ### Why would those edits help? FAS is a classic cell-death receptor. If CAR-T cells trigger that pathway in themselves, they burn out faster. Knocking out FAS can help them survive longer. RHOG is trickier — it sits in signaling and cytoskeletal pathways that shape how immune cells activate, move, and exhaust. The broad idea is simple: keep the engineered cells alive and functional for longer inside a hostile tumor. (nature.com) ### Does that mean edited CAR-T already beat unedited CAR-T in gastric cancer patients? Not from the evidence I could verify. I found the randomized gastric trial for satri-cel and the separate RHOG/FAS preclinical papers, but not a primary clinical paper showing a gastric cancer cohort where RHOG- and FAS-edited CAR-T directly improved survival over unedited contro(nature.com)er, yes; RHOG/FAS as the proven reason for that breakthrough, no. (thelancet.com) ### Why does the distinction matter? Because the field is moving from “can CAR-T work in solid tumors at all?” to “how do we engineer the next generation?” Mixing a validated phase 2 result with preclinical editing hypotheses makes the science sound further along than it is. The satri-cel data say solid-tumor CAR-T can work. T(thelancet.com) story. (thelancet.com) ### Bottom line? The real news is bigger than the meme version — CAR-T finally posted a randomized win in advanced gastric cancer. But the RHOG/FAS angle is best read as the sequel: promising engineering biology that could extend persistence in future products, not the proven explanation for the 7.9-versus-5.5-month trial result. (thelancet.com)